Half the Dose for Hepatitis C Remission
Less sometimes is worth more! Finding the "sweet spot" for taking a drug while minimizing the downside of drug exposure is the goal of many drug researchers. A new multi-continent study has done just.
FDA Hepatitis Update - Pegasys and Copegus
On August 22, 2011, the FDA approved the combination of Pegasys and Copegus for the treatment of chronic hepatitis C virus ( HCV ) infection in pediatric patients 5 through 17 years of age.
Help is Here, but You Aren't Eligible
Lack of health insurance coverage may affect hepatitis C patients' access to current antiviral treatments, according to a new study.